gip glp 1 tirzepatide (GLP-1 / GIP) Tirzepatide (TZP) differentially induces internalization

During the initial weeks of semaglutide treatment, you may observe early signs of weight loss , but the most significant changes typically occur after a few months, as the medication reaches its full therapeutic potential

Obesity increases the risk of death almost 3-fold

For IBS-D, cholestyramine/colestipol, eluxadoline, and rifaximin are not associated with mortality

Semaglutide has been approved by the FDA and many other countries regulatory bodies for both of its two main usesmanagement of type 2 diabetes and chronic weight management in adults with obesity or those who are overweight with at least one weight-related condition, such as hypertension or high cholesterol